G

Genomed SA
WSE:GEN

Watchlist Manager
Genomed SA
WSE:GEN
Watchlist
Price: 26.2 PLN 4.8% Market Closed
Market Cap: 34.6m PLN
Have any thoughts about
Genomed SA?
Write Note

Genomed SA
Total Liabilities & Equity

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Genomed SA
Total Liabilities & Equity Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Total Liabilities & Equity CAGR 3Y CAGR 5Y CAGR 10Y
G
Genomed SA
WSE:GEN
Total Liabilities & Equity
zł12.1m
CAGR 3-Years
7%
CAGR 5-Years
5%
CAGR 10-Years
N/A
M
Mabion SA
WSE:MAB
Total Liabilities & Equity
zł179.3m
CAGR 3-Years
-2%
CAGR 5-Years
11%
CAGR 10-Years
2%
R
Read Gene SA
WSE:RDG
Total Liabilities & Equity
zł11.3m
CAGR 3-Years
-11%
CAGR 5-Years
-6%
CAGR 10-Years
0%
B
Bioton SA
WSE:BIO
Total Liabilities & Equity
zł790.4m
CAGR 3-Years
-3%
CAGR 5-Years
-3%
CAGR 10-Years
-9%
U
Urteste SA
WSE:URT
Total Liabilities & Equity
zł29.6m
CAGR 3-Years
250%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
S
Synthaverse SA
WSE:SVE
Total Liabilities & Equity
zł293.2m
CAGR 3-Years
38%
CAGR 5-Years
27%
CAGR 10-Years
10%
No Stocks Found

Genomed SA
Glance View

Market Cap
34.6m PLN
Industry
Biotechnology

Genomed SA engages in the provision of medical diagnostic services. The company is headquartered in Warsaw, Woj. Mazowieckie. The company went IPO on 2011-05-30. The company develops molecular diagnostics based on deoxyribonucleic acid (DNA) sequencing, with a special focus on the Next Generation Sequencing (NGS) method. The Company’s offer includes the analysis of gene mutations responsible for over 150 congenital diseases, such as infertility, predisposition to cancer, cystic fibrosis (CF), Alzheimer's disease, hearing loss, coeliac disease, cardiomyopathy and obesity, among others. The Company’s activities are directed toward introducing genomic technology to personalized medicine and creating a clinic offering gene treatments. The firm also provides diverse DNA sequencing, analysis and synthesis services for research and the biotechnological market.

GEN Intrinsic Value
25.37 PLN
Overvaluation 3%
Intrinsic Value
Price
G

See Also

What is Genomed SA's Total Liabilities & Equity?
Total Liabilities & Equity
12.1m PLN

Based on the financial report for Dec 31, 2023, Genomed SA's Total Liabilities & Equity amounts to 12.1m PLN.

What is Genomed SA's Total Liabilities & Equity growth rate?
Total Liabilities & Equity CAGR 5Y
5%

Over the last year, the Total Liabilities & Equity growth was 17%. The average annual Total Liabilities & Equity growth rates for Genomed SA have been 7% over the past three years , 5% over the past five years .

Back to Top